Rosuvastatin alone or with extended-releasen niacin: a new therapeutic option for patients with combined hyperlipidemia
Rosuvastatin alone or with extended-releasen niacin: a new therapeutic option for patients with combined hyperlipidemia
Combination therapy with a statin and niacin may provide optimal therapy for patients with combined hyperlipidemia and low levels of high-density lipoprotein (HDL) cholesterol. The authors assessed the efficacy and safety of rosuvastatin monotherapy, extended-release (ER) niacin monotherapy, or rosuvastatin and ER niacin combined therapy in patients with atherogenic dyslipidemia. In a 24-week, open-label, multicenter trial, men and women aged ?18 years with fasting levels of total cholesterol ?200 mg/dL, HDL cholesterol ?45 mg/dL, triglycerides 200-800 mg/dL, and apolipoprotein B ?110 mg/dL were randomly assigned to one of four treatment groups: rosuvastatin 10-40 mg, ER niacin 0.5-2 g, rosuvastatin 40 mg plus ER niacin 0.5-1 g, or rosuvastatin 10 mg plus ER niacin 0.5-2 g. Daily doses of rosuvastatin 40 mg monotherapy reduced low-density lipoprotein (LDL) cholesterol and non-HDL cholesterol levels significantly more than did either ER niacin 2 g monotherapy or rosuvastatin 10 mg combined with ER niacin 2 g. Addition of ER niacin 1 g to rosuvastatin 40 mg did not further reduce total or non-HDL cholesterol. Triglyceride reductions were similar among the four treatment groups. ER niacin mono- and combined therapy produced significantly greater rises in HDL cholesterol and apolipoprotein A-1 than did rosuvastatin monotherapy. Rosuvastatin monotherapy was better tolerated than ER niacin taken either alone or with rosuvastatin. In this study, rosuvastatin very effectively improved the three major lipoprotein-lipid abnormalities of combined hyperlipidemia.
176-181
Capuzzi, David M.
e6993ee2-2b00-4cab-8fb1-c27ad5f0d799
Morgan, John M.
ac98099e-241d-4551-bc98-709f6dfc8680
Carey, Christina M.
5282c0d2-10af-461e-8000-721cf0efea73
Intenzo, Charles
d8566107-36e9-4e35-8210-e62e18aed458
Tulenko, Thomas
fe8dec4e-8984-4c7b-a11f-0adc854bc618
Kearney, Dana
c9ab52ff-db53-4234-99d5-987b68a0dbc0
Walker, Kalen
738faa49-cada-4af9-a156-5337ececd5f2
Cressman, Michael D.
3396df8b-e3e8-49fd-937a-5fc224cddc08
2004
Capuzzi, David M.
e6993ee2-2b00-4cab-8fb1-c27ad5f0d799
Morgan, John M.
ac98099e-241d-4551-bc98-709f6dfc8680
Carey, Christina M.
5282c0d2-10af-461e-8000-721cf0efea73
Intenzo, Charles
d8566107-36e9-4e35-8210-e62e18aed458
Tulenko, Thomas
fe8dec4e-8984-4c7b-a11f-0adc854bc618
Kearney, Dana
c9ab52ff-db53-4234-99d5-987b68a0dbc0
Walker, Kalen
738faa49-cada-4af9-a156-5337ececd5f2
Cressman, Michael D.
3396df8b-e3e8-49fd-937a-5fc224cddc08
Capuzzi, David M., Morgan, John M., Carey, Christina M., Intenzo, Charles, Tulenko, Thomas, Kearney, Dana, Walker, Kalen and Cressman, Michael D.
(2004)
Rosuvastatin alone or with extended-releasen niacin: a new therapeutic option for patients with combined hyperlipidemia.
Preventive Cardiology, 7 (4), .
Abstract
Combination therapy with a statin and niacin may provide optimal therapy for patients with combined hyperlipidemia and low levels of high-density lipoprotein (HDL) cholesterol. The authors assessed the efficacy and safety of rosuvastatin monotherapy, extended-release (ER) niacin monotherapy, or rosuvastatin and ER niacin combined therapy in patients with atherogenic dyslipidemia. In a 24-week, open-label, multicenter trial, men and women aged ?18 years with fasting levels of total cholesterol ?200 mg/dL, HDL cholesterol ?45 mg/dL, triglycerides 200-800 mg/dL, and apolipoprotein B ?110 mg/dL were randomly assigned to one of four treatment groups: rosuvastatin 10-40 mg, ER niacin 0.5-2 g, rosuvastatin 40 mg plus ER niacin 0.5-1 g, or rosuvastatin 10 mg plus ER niacin 0.5-2 g. Daily doses of rosuvastatin 40 mg monotherapy reduced low-density lipoprotein (LDL) cholesterol and non-HDL cholesterol levels significantly more than did either ER niacin 2 g monotherapy or rosuvastatin 10 mg combined with ER niacin 2 g. Addition of ER niacin 1 g to rosuvastatin 40 mg did not further reduce total or non-HDL cholesterol. Triglyceride reductions were similar among the four treatment groups. ER niacin mono- and combined therapy produced significantly greater rises in HDL cholesterol and apolipoprotein A-1 than did rosuvastatin monotherapy. Rosuvastatin monotherapy was better tolerated than ER niacin taken either alone or with rosuvastatin. In this study, rosuvastatin very effectively improved the three major lipoprotein-lipid abnormalities of combined hyperlipidemia.
This record has no associated files available for download.
More information
Published date: 2004
Additional Information:
ID: 3217
Identifiers
Local EPrints ID: 25347
URI: http://eprints.soton.ac.uk/id/eprint/25347
ISSN: 1520-037X
PURE UUID: 367460ef-24ef-4771-ace7-680345aa6d23
Catalogue record
Date deposited: 11 Apr 2006
Last modified: 07 Jan 2022 22:17
Export record
Contributors
Author:
David M. Capuzzi
Author:
John M. Morgan
Author:
Christina M. Carey
Author:
Charles Intenzo
Author:
Thomas Tulenko
Author:
Dana Kearney
Author:
Kalen Walker
Author:
Michael D. Cressman
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics